Prelude Therapeutics Incorporated

NASDAQ:PRLD

1.27 (USD) • At close November 7, 2024
Bedrijfsnaam Prelude Therapeutics Incorporated
Symbool PRLD
Munteenheid USD
Prijs 1.27
Beurswaarde 69,881,072
Dividendpercentage 0%
52-weken bereik 1.1 - 6.8
Industrie Biotechnology
Sector Healthcare
CEO Dr. Krishna Vaddi D.V.M., Ph.D.
Website https://www.preludetx.com

An error occurred while fetching data.

Over Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in

Vergelijkbare Aandelen

bluebird bio, Inc. logo

bluebird bio, Inc.

BLUE

0.382 USD

VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

VTGN

3.12 USD

Singular Genomics Systems, Inc. logo

Singular Genomics Systems, Inc.

OMIC

23.3 USD

KalVista Pharmaceuticals, Inc. logo

KalVista Pharmaceuticals, Inc.

KALV

11.18 USD

Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc.

COGT

10.05 USD

PepGen Inc. logo

PepGen Inc.

PEPG

5.63 USD

VBI Vaccines Inc. logo

VBI Vaccines Inc.

VBIV

0.065 USD

Zentek Ltd. logo

Zentek Ltd.

ZTEK

1.25 USD

Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc.

STRO

4.16 USD

Viemed Healthcare, Inc. logo

Viemed Healthcare, Inc.

VMD

9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)